0001104659-23-099360.txt : 20230908 0001104659-23-099360.hdr.sgml : 20230908 20230908171030 ACCESSION NUMBER: 0001104659-23-099360 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230908 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230908 DATE AS OF CHANGE: 20230908 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Apollo Medical Holdings, Inc. CENTRAL INDEX KEY: 0001083446 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] IRS NUMBER: 870042699 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37392 FILM NUMBER: 231246065 BUSINESS ADDRESS: STREET 1: 1668 S. GARFIELD AVENUE STREET 2: 2ND FLOOR CITY: ALHAMBRA STATE: CA ZIP: 91801 BUSINESS PHONE: (626) 282-0288 MAIL ADDRESS: STREET 1: 1668 S. GARFIELD AVENUE STREET 2: 2ND FLOOR CITY: ALHAMBRA STATE: CA ZIP: 91801 FORMER COMPANY: FORMER CONFORMED NAME: SICLONE INDUSTRIES INC DATE OF NAME CHANGE: 19990413 8-K 1 tm2325794d1_8k.htm FORM 8-K
0001083446 false 0001083446 2023-09-08 2023-09-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): September 8, 2023

 

APOLLO MEDICAL HOLDINGS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware 001-37392 95-4472349
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)

 

1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801

(Address of Principal Executive Offices) (Zip Code)

 

(626) 282-0288

Registrant’s Telephone Number, Including Area Code

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock AMEH The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

   

 

 

Item 1.01Entry into a Material Definitive Agreement.

 

On September 8, 2023, Apollo Medical Holdings, Inc. (the “Company”) entered into the Second Amendment to Amended and Restated Credit Agreement and Waiver (the “Amendment”) to the Amended and Restated Credit Agreement, dated as of June 16, 2021, by and among the Company, as borrower, the lenders party thereto, and Truist Bank, as administrative agent (as amended, the “Credit Agreement”). Among other things, the Amendment (i) increased the letter of credit sub-facility from $25.0 million to $50.0 million; (ii) revised the form of compliance certificate required to be submitted by the Company to the lenders on a quarterly basis; and (iii) waived the Specified Events of Default (as defined in the Amendment) that occurred under the Credit Agreement, relating to the Company’s calculation of Consolidated Total Net Leverage Ratio (as defined in the Credit Agreement) and payment of certain interest and letter of credit fees, in each case, for the periods from the quarter ended September 30, 2021 through the quarter ended March 31, 2023 (the “Prior Periods”). The Company also provided the lenders with updated calculations of Consolidated Total Net Leverage Ratio and Consolidated Interest Coverage Ratio (each as defined in the Credit Agreement) for the Prior Periods and paid an aggregate fee of $200,000 to the lenders, as payment in full of the interest and letter of credit fees due for the Prior Periods as a result of the Specified Events of Default.

 

The above description of the Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 2.03Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this item.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.		   Description
10.1   Second Amendment to Amended and Restated Credit Agreement and Waiver, dated as of September 8, 2023, by and among Apollo Medical Holdings, Inc., as borrower, Network Medical Management, Inc., as guarantor, the lenders party thereto, and Truist Bank, as administrative agent, issuing bank and the swingline lender.
104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  APOLLO MEDICAL HOLDINGS, INC.
   
Date: September 8, 2023 By: /s/ Thomas S. Lam
  Name: Thomas S. Lam, M.D., M.P.H.
  Title: Co-Chief Executive Officer and President

 

 

 

 EX-10.1 2 tm2325794d1_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

 

SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT AND WAIVER

  

THIS SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT AND WAIVER, dated as of September 8, 2023 (this “Amendment”), is made by and among APOLLO MEDICAL HOLDINGS, INC., a Delaware corporation (the “Borrower”), NETWORK MEDICAL MANAGEMENT, INC., a California corporation (the “Guarantor”), each of the banks and other financial institutions signatory hereto as “Lenders” and TRUIST BANK, in its capacity as Administrative Agent (in such capacity, the “Administrative Agent”) for the Lenders, as Issuing Bank and as the Swingline Lender.

 

W I T N E S S E T H:

 

WHEREAS, the Borrower, the Lenders and the Administrative Agent are parties to that certain Amended and Restated Credit Agreement dated as of June 16, 2021 (as amended by that certain First Amendment to Amended and Restated Credit Agreement dated as of December 20, 2022, and as otherwise amended, restated, supplemented or modified from time to time prior to the date hereof, the “Existing Credit Agreement”);

 

WHEREAS, the Administrative Agent and the Lenders have been made aware that certain Events of Default have occurred and are continuing under (a) Sections 8.1(c) and 8.1(d) of the Credit Agreement (collectively, the “Specified Reporting Events of Default”) as a result of the Borrower’s failure to accurately calculate and report the Consolidated Total Net Leverage Ratio in the Compliance Certificates delivered for the reporting periods commencing with the Fiscal Quarter ended September 30, 2021 through the Fiscal Quarter ended March 31, 2023 (the “Subject Periods”) due to the failure to (i) calculate “Consolidated Total Net Debt” as required by the definition thereof by (A) incorrectly deducting debt issuance costs from the total principal amount of Indebtedness (which is permitted to be deducted under GAAP, but is not permitted to be deducted for purposes of determining “Consolidated Total Net Debt” under the Existing Credit Agreement), (B) not including the face amount of issued and outstanding Letters of Credit as “Consolidated Total Net Debt”, (C) not including Capital Lease Obligations as “Consolidated Total Net Debt” and (D) not including the deferred acquisition consideration (including the requirement to purchase the remaining equity of a target) as “Consolidated Total Net Debt” resulting from the acquisitions of David C.P. Chen M.D., Inc., DBA Diagnostic Medical Group and Sun Clinical Laboratories, and (ii) reduce Consolidated EBITDA by an amount equal to the net income attributable to the Capital Stock of David C.P. Chen M.D., Inc., DBA Diagnostic Medical Group and Sun Clinical Laboratories that is owned by unaffiliated third parties (as required by clause (iii)(c) of the definition of “Consolidated EBITDA”); and (b) Section 8.1(b) of the Credit Agreement (the “Specified Payment Events of Default”; and together with the Specified Reporting Events of Default, collectively, the “Specified Events of Default”) as a result of the Borrower’s failure to pay the appropriate amount of interest and letter of credit fees for certain prior periods due to the application of an incorrect Applicable Margin resulting from the Specified Reporting Events of Default;

 

WHEREAS, the Borrower has requested that the Administrative Agent and the Required Lenders (1) waive the Specified Events of Default and (2) amend certain provisions of the Existing Credit Agreement, all as more particularly set forth below; and

 

WHEREAS, subject to the terms and conditions set forth herein, the Administrative Agent and the Required Lenders are willing to waive the Specified Events of Default and amend the Existing Credit Agreement.

 

 

 

 

NOW, THEREFORE, for and in consideration of the above premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties hereto, the parties hereto hereby agree as follows:

 

Section 1. Defined Terms. Except as otherwise defined herein, capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Existing Credit Agreement, as amended by this Amendment (the “Amended Credit Agreement”).

 

Section 2. Amendments to Existing Credit Agreement and Loan Documents. The Loan Parties, the Administrative Agent and the Lenders signatory hereto (which, for the avoidance of doubt, constitute “Required Lenders”) hereby agree to the following amendments:

 

(a)          Section 1.1 of the Existing Credit Agreement is hereby amended by deleting the reference to “$25,000,000” in the definition of “LC Commitment” and substituting reference to “$50,000,000” in lieu thereof.

 

(b)          Section 10.1(a)(i) of the Existing Credit Agreement is hereby amended by deleting the “To the Borrower:” address and contact information and substituting the following new address and contact information for the Borrower in lieu thereof:

 

  “To the Borrower: Apollo Medical Holdings, Inc.
1668 S. Garfield Avenue, 2nd Floor
Alhambra, CA 91801
Attention: Chan Basho, CFO
Email:
CBasho@networkmedicalmanagement.com
Telephone Number: 626-943-6008”

 

(c)          The Exhibits to the Existing Credit Agreement are hereby amended to replace Exhibit 5.1(c) (Form of Compliance Certificate) in its entirety with the corresponding new Exhibit 5.1(c) set forth in Annex B attached hereto.

 

Section 3. Conditions Precedent to Effectiveness. This Amendment shall become effective as of the date on which each of the following conditions precedent are satisfied (such date, the “Second Amendment Effective Date”):

 

(a)          the Administrative Agent (or its counsel) shall have received a counterpart of this Amendment duly executed by each of the Borrower, the Guarantor, the Administrative Agent, and the Required Lenders;

 

(b)          the Administrative Agent shall have received $200,000 for the benefit of each Lender in accordance with its Pro Rata Share of the Commitments (notwithstanding whether or not such Lender shall have signed this Amendment), which represents payment in full to the Lenders for the Specified Payment Events of Default;

 

(c)          substantially concurrent with the effectiveness of this Amendment, the Administrative Agent shall have received evidence of payment by the Borrower of all reasonable, out-of-pocket fees, charges and disbursements of Alston & Bird LLP, counsel to the Administrative Agent, and any other fees payable pursuant to the Loan Documents; and

 

2

 

 

(d)          the representations and warranties in Sections 4 and 5 hereof (including as relates to Annex A attached hereto) shall be true and correct in all material respects on and as of the date hereof (other than those representations and warranties that are expressly qualified by a Material Adverse Effect or other materiality, in which case such representations and warranties shall be true and correct in all respects).

 

The Loan Parties, the Lenders and the Administrative Agent hereby acknowledge and agree that as of the date hereof, the conditions precedent to effectiveness as set forth in this Section 3 have been satisfied and this Amendment is effective as of the date hereof.

 

Section 4. Representations. The Loan Parties represent and warrant to the Administrative Agent and the Lenders that:

 

(a)          Power and Authority. Each of the Loan Parties has the power and authority to execute, deliver and perform the terms and provisions of this Amendment and the Amended Credit Agreement, and have taken all necessary corporate or equivalent action to duly authorize the execution, delivery and performance of this Amendment. This Amendment has been duly executed and delivered by each Loan Party. Each of this Amendment and the Amended Credit Agreement constitutes the legal, valid and binding obligation of the Borrower or the Guarantor (as the case may be) enforceable in accordance with its terms, except to the extent that the enforceability thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws generally affecting creditors’ rights and by equitable principles.

 

(b)          No Violation. The execution, delivery and performance by the other Loan Parties of this Amendment, and compliance by them with the terms and provisions of the Amended Credit Agreement: (i) will not violate any Requirement of Law or any judgment, order or ruling of any Governmental Authority, (ii) will not violate or result in a default under any Contractual Obligation of the Borrower or any of its Subsidiaries or any of its assets or give rise to a right thereunder to require any payment to be made by the Borrower or any of its Subsidiaries, or (iii) will not result in the creation or imposition of any Lien on any asset of any Loan Party except Liens created under the Loan Documents.

 

(c)          Governmental Approvals. No order, consent, approval, license, authorization or validation of, or filing, recording or registration with (except for those that (x) have otherwise been obtained or made on or prior to the date of the effectiveness of this Amendment and which remain in full force and effect on such date and (y) the failure of which to obtain or make could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect), or exemption by, any Governmental Authority, is required to authorize, or is required in connection with, (i) the execution, delivery and performance of this Amendment by the Loan Parties or (ii) the legality, validity, binding effect or enforceability of the Amended Credit Agreement.

 

(d)          No Default. No Default or Event of Default has occurred and is continuing as of the date hereof (other than the Specified Events of Default before giving effect to the waiver set forth herein) and no Default or Event of Default will exist immediately after giving effect to this Amendment.

 

(e)          Annex A; Revised Applicable Margin. The true, correct and complete calculations of the “Consolidated Total Net Leverage Ratio” and “Consolidated interest Coverage Ratio” for each of the Subject Periods are attached hereto as Annex A (the “Revised Calculations”), and the disclosures, representations and warranties relating thereto as set forth in Annex A are accurate in all material respects. As a result of the revised Consolidated Total Net Leverage Ratio Calculations set forth in Annex A, the Borrower acknowledges and agrees that the Applicable Margin reflected by “Pricing Level III” on Schedule I to the Existing Credit Agreement should have applied as a result of the Compliance Certificate delivered for the Fiscal Quarter ended March 31, 2023 (in lieu of “Pricing Level II”, which was applied for each such period) and, as a result, additional interest and letter of credit fees should have been paid to the Lenders in accordance with their Pro Rata Share of the Commitments during such periods. It is understood and agreed that all of such interest and letter of credit fees are being paid to the Administrative Agent for the benefit of the Lenders as a condition to this Amendment pursuant to Section 3(b) hereof.

 

3

 

 

Section 5. Reaffirmation of Representations. The Borrower and the other Loan Parties hereby repeat and reaffirm in all material respects all representations and warranties made to the Administrative Agent and the Lenders in the Existing Credit Agreement and the other Loan Documents on and as of the date hereof (and after giving effect to this Amendment) with the same force and effect as if such representations and warranties were set forth in this Amendment in full (except to the extent that such representations and warranties relate expressly to an earlier date, in which case such representations and warranties were true and correct in all material respects as of such earlier date).

 

Section 6. Limited Waiver. The Administrative Agent and the Required Lenders hereby waive the Specified Events of Default. The waiver contained in this Section 6 shall not amend any covenant, term or provision in the Credit Agreement or hinder, restrict or otherwise modify the rights and remedies of the Lenders and the Administrative Agent following the occurrence of any other present or future Default or Event of Default under the Credit Agreement or any other Loan Document. For the avoidance of doubt, if it is later determined by the Loan Parties or the Lenders that the Revised Calculations are incorrect in any material respect as set forth in Annex A, there shall be (and have been) an Event of Default outstanding as of the date that such inaccuracy was first required to be reported under the Existing Credit Agreement.

 

Section 7. No Further Amendments; Ratification of Liability. Except as expressly amended hereby, the Existing Credit Agreement and each of the other Loan Documents, as amended hereby, shall remain in full force and effect in accordance with their respective terms, and the Lenders and the Administrative Agent hereby require strict compliance with the terms and conditions of the Amended Credit Agreement and the other Loan Documents, as amended hereby, in the future. No Loan Party has any knowledge of any challenge to the Administrative Agent’s or any Lender’s claims arising under the Loan Documents. Each of the Borrower and the other Loan Parties hereby (i) ratifies, confirms and reaffirms its respective liabilities, payment and performance obligations (contingent or otherwise) and each and every term, covenant and condition set forth in the Amended Credit Agreement and the other Loan Documents to which it is a party, all as amended by this Amendment and (ii) acknowledges and agrees that this Amendment shall not in any way affect the validity and enforceability of any Loan Document, as amended hereby, to which it is a party, or reduce, impair or discharge the obligations of the Borrower or any other Loan Party. The Guarantor hereby acknowledges its receipt of a copy of this Amendment and its review of the terms and conditions hereof and consents to the terms and conditions of this Amendment and the transactions contemplated hereby. The Guarantor hereby (a) affirms and confirms its guarantees under the Guaranty and Security Agreement, and (b) agrees that (i) Guaranty and Security Agreement shall continue to be in full force and effect and (ii) all guarantees under the Guaranty and Security Agreement shall continue to be in full force and effect and shall accrue to the benefit of the Lenders. The Lenders’ agreement to the terms of this Amendment or any other amendment of the Existing Credit Agreement or any other Loan Document shall not be deemed to establish or create a custom or course of dealing between the Borrower or any other Loan Party or the Lenders, or any of them. This Amendment shall be deemed to be a “Loan Document” for all purposes under the Amended Credit Agreement. After the effectiveness of this Amendment, each reference to the Existing Credit Agreement in any of the Loan Documents shall be deemed to be a reference to the Amended Credit Agreement.

 

4

 

 

Section 8. Miscellaneous. Sections 10.5 (Governing Law; Jurisdiction; Consent to Service of Process), 10.6 (Waiver of Jury Trial), 10.8 (Counterparts; Integration), 10.10 (Severability) and 10.21 (Electronic Signatures), of the Amended Credit Agreement are hereby incorporated by reference into this Amendment and shall apply hereto mutatis mutandis.

  

[Signature Pages Follow]

 

5

 

 

IN WITNESS WHEREOF, the Borrower, the Guarantor, the Lenders and the Administrative Agent have caused this Second Amendment to Amended and Restated Credit Agreement and Waiver to be duly executed by their respective duly authorized officers and representatives as of the day and year first above written.

 

  bORROWER:
   
  APOLLO MEDICAL HOLDINGS, INC.
   
   
  By: /s/ Brandon Sim
  Name: Brandon Sim
  Title: Co-Chief Executive Officer
   
  By: /s/ Chandan Basho
  Name: Chandan Basho
  Title: Chief Strategy Officer and Chief Financial Officer
   
   
  GUARANTOR:
   
  network medical management, inc.
   
   
  By: /s/ Thomas S. Lam
  Name: Thomas S. Lam, M.D., M.P.H
  Title: Chief Executive Officer

 

APOLLO MEDICAL HOLDINGS, INC.

SECOND AMENDMENT TO A&R CREDIT AGREEMENT AND WAIVER

SIGNATURE PAGE

 

 

 

  TRUIST BANK, as Administrative Agent, as an Issuing Bank, as the Swingline Lender and as a Lender
   
   
  By: /s/ Anton Brykalin
  Name: Anton Brykalin
  Title: Director

 

APOLLO MEDICAL HOLDINGS, INC.

SECOND AMENDMENT TO A&R CREDIT AGREEMENT AND WAIVER

SIGNATURE PAGE

 

 

 

  JPMORGAN CHASE BANK, N.A., as a Lender
   
  By: /s/ Ling Li
    Name: Ling Li
    Title: Executive Director

 

APOLLO MEDICAL HOLDINGS, INC.

SECOND AMENDMENT TO A&R CREDIT AGREEMENT AND WAIVER

SIGNATURE PAGE

 

 

 

  MUFG UNION BANK, N.A., as a Lender
   
   
  By: /s/ Erik Siegfried
    Name: Erik Siegfried
    Title: Vice President

 

APOLLO MEDICAL HOLDINGS, INC.

SECOND AMENDMENT TO A&R CREDIT AGREEMENT AND WAIVER

SIGNATURE PAGE

 

 

 

  PREFERRED BANK, as a Lender
   
  By: /s/ Samuel Leung
    Name: Samuel Leung
    Title: Senior Vice President

 

APOLLO MEDICAL HOLDINGS, INC.

SECOND AMENDMENT TO A&R CREDIT AGREEMENT AND WAIVER

SIGNATURE PAGE

 

 

 

  FIFTH THIRD BANK, NATIONAL ASSOCIATION, as a Lender
   
  By: /s/ Thomas Avery
    Name: Thomas Avery
    Title: Managing Director

 

APOLLO MEDICAL HOLDINGS, INC.

SECOND AMENDMENT TO A&R CREDIT AGREEMENT AND WAIVER

SIGNATURE PAGE

 

 

 

  BMO BANK N.A., successor in interest to
  BANK OF THE WEST, as a Lender
   
  By: /s/ Shikha Rehman
    Name: Shikha Rehman
    Title: Director

 

APOLLO MEDICAL HOLDINGS, INC.

SECOND AMENDMENT TO A&R CREDIT AGREEMENT AND WAIVER

SIGNATURE PAGE

 

 

 

  ROYAL BANK OF CANADA, as a Lender
   
  By: /s/ Emily Grams
    Name: Emily Grams
    Title: Authorized Signatory

 

APOLLO MEDICAL HOLDINGS, INC.

SECOND AMENDMENT TO A&R CREDIT AGREEMENT AND WAIVER

SIGNATURE PAGE

 

 

 

  THE TORONTO DOMINION BANK, NEW YORK BRANCH, as a Lender
   
  By: /s/ Victoria Roberts
    Name: Victoria Roberts
    Title: Authorized Signatory

 

APOLLO MEDICAL HOLDINGS, INC.

SECOND AMENDMENT TO A&R CREDIT AGREEMENT AND WAIVER

SIGNATURE PAGE

 

 

 

  WELLS FARGO BANK, NATIONAL ASSOCIATION, as a Lender
   
  By: /s/ Ashley Griffith
    Name: Ashley Griffith
    Title: Assistant Vice President

 

APOLLO MEDICAL HOLDINGS, INC.

SECOND AMENDMENT TO A&R CREDIT AGREEMENT AND WAIVER

SIGNATURE PAGE

 

 

 

  CITY NATIONAL BANK, as a Lender
   
  By: /s/ Eric Rezai
    Name: Eric Rezai
    Title: Vice President

 

APOLLO MEDICAL HOLDINGS, INC.

SECOND AMENDMENT TO A&R CREDIT AGREEMENT AND WAIVER

SIGNATURE PAGE

 

 

 EX-101.SCH 3 ameh-20230908.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ameh-20230908_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ameh-20230908_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Sep. 08, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 08, 2023
Entity File Number 001-37392
Entity Registrant Name APOLLO MEDICAL HOLDINGS, INC.
Entity Central Index Key 0001083446
Entity Tax Identification Number 95-4472349
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1668 S. Garfield Avenue
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town Alhambra
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91801
City Area Code 626
Local Phone Number 282-0288
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol AMEH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 tm2325794d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001083446 2023-09-08 2023-09-08 iso4217:USD shares iso4217:USD shares 0001083446 false 8-K 2023-09-08 APOLLO MEDICAL HOLDINGS, INC. DE 001-37392 95-4472349 1668 S. Garfield Avenue 2nd Floor Alhambra CA 91801 626 282-0288 false false false false Common Stock AMEH NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://apollomed.net/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2325794d1_8k.htm ameh-20230908.xsd ameh-20230908_lab.xml ameh-20230908_pre.xml tm2325794d1_ex10-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2325794d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2325794d1_8k.htm" ] }, "labelLink": { "local": [ "ameh-20230908_lab.xml" ] }, "presentationLink": { "local": [ "ameh-20230908_pre.xml" ] }, "schema": { "local": [ "ameh-20230908.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "AMEH", "nsuri": "http://apollomed.net/20230908", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2325794d1_8k.htm", "contextRef": "AsOf2023-09-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://apollomed.net/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2325794d1_8k.htm", "contextRef": "AsOf2023-09-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001104659-23-099360-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-099360-xbrl.zip M4$L#!!0 ( $Z)*%>UL>G6*P, .8+ 1 86UE:"TR,#(S,#DP."YX MI7T07W[";K\V-T@P.HHL_ 0&#%Q3&ZQS0R%GY%* AT MSH.0@@+M2")5T;Y3K'C(MC?0O0?F<]%M-R>ZSTJ%LNJZP^'08?P-#[EXD8[' M@\T$.PJK2$[4"J-"^MN,?DVD-R'OX<;^\'#4)H\#8$=1"Y>?O >,OT+OUO_] MU-Z#GR\C%9P=]![8M\/QY>O=#6>=3O?[V#M[Z/J-JR1D37K/$&"DF\%DW3+U MI>4-RPX7 [=4*!3=Q^M6)\99"; ZHH2]+(,7*Y6*&WLS: XYZ@F:29==X^YA M"1-E[25K\(1)A9DWA_?5A# +WG<3YQR4+(4>)%"207U8P$GPG %_<[5#XTOE M#!A)>X!Q. 'WL>S%HJEC#BR%R@.U<1%DJW$(77R98'')*>0"^ MPR#1+50*1WJU* 3 U!47P07T<41U)J\1IJ1/P+>0PF( RDR9#+$'[\EELXH9 MXWJD]5ZE%F,+0Z)G=F+0)M/CJN 4?NCDD3GHG5H1PWC=I%]&=J-/\UC%3>_8F3N""W"0Q"*Z)&>N0B2U(DR]+N9 M,,C$D19R_V'E%/>VK5Q3@/['DEM&/U]KS9U?+?V\N'XU72X7"K'<(J^[2)-/ M0(M[L=0:BGFR,YYM3':Q9)>+SDCZTTRW26+Z!K9+(N/MD,2*ZWQ9?+D*;@[Q M"&T:=,5G86W0I1P7J)*99><49C\B?Y%#++-5$G/M])5PC801+=FZC^7BZG3> M8\;/,?4$L#!!0 ( $Z)*%&ULS9U=;^.X%8;O"_0_<-V;%AC'XP0MD.QD%QE/LC VFV1CSVS; M1;&@)<810I,!)2?VOR\IB;)$\4A*BI*$"]WPB+N?AZ/Z_J?O)$1?K MR?''C]/)/W^Y7D2/9(/'"5/'+2(C':5JL<5-3T]/)WFIEK:4NY6@>A\G$VVG MJEF6)AWZFI,T.4MS>]<\PEG>[;V[0:!"_6^L96.U:3P]'I],CW9I/-('/S^" M@E-R3QY0WLRS;/\L44H31<*HW/8HR(/=#!5BHN(GC*QQ1F*UHU.UH^D_U([^ M4FZ^QBM"1T@I)1]@NTX;=95!$]=F[XA(>'S)WN?:C/9D7WYW1/8_-* >[[P) M2YYA^B[S]4CGMF_(^X[X(<[]D9;C/'G?D:Y%_E]L9VW+;SZ\]N-*U<9K^:EA MD>PR.8&16)M4572,P/D>\HFAK+NJG4>->JD:S;EHMUW-C'F=*8F.UOQE$I-$ MUGU\HCZ,U8>\V?(_?\RX7 E7-.!]9RB>F):6\$-H7%E%/XTK% M).)R:GK.QK0XC$7X@^ ;ZV[+5G-+X1]T5<47AT7N C#:D F2\JV(R)MZI>X6 M.DJEHPV5"K6D(FS\=3'Z(=>@W[7J/Y\FAUH<=+1< FTWA&5+6:.E!:=;3+;ZOJ8)"X&V,9B$FM;3P'Y/UHF: M6I0%=7Y+U,:.80S0NQ[Z.VV;L1-!][U0M)2NN0"LFF@8LJ#H ML'L# :GD?AE9"LS21 U@O9"TITP(9-7MK*H(@![8',Y!&H# D'F\L7M3J7RZ2!C:WI?<+3LMW% M3R4.%B'3X4"*\C"DXCR15+L-T<-02^F:'L"JR8TA"XH8NS>0E4*.E':T@\L+:MV5"I9@*"8WOHP47HOD,RV0C1< MPS,.+'5V4[;';'5_%M % 4J/N=9=VT+> ,73#'3)LB3;J^?I;K:;%1&6QK4E MKMB S&DFS/(@6 !,F0P4,J1TJ!!ZZ7E]EX!EZB%&L#FFS"T!=I--"IJ:@$BP M&@-H.&CS9TJ]$#&3(Y/ =,YBLON9[,%VM71NF0!L-J$P1 %187<&8%&*4:Y& M4NX%C#N1;+#8+Y*H9ZIH"]VB 1EMLF&J H(#L ;04:K18C[S.9,L\6X>2U"3 MAZ1X'KR'$E#O%I8>VTUF '% Z'0[! B20:@9Y1.D.8NX>.:UQQUF?"L'P/V, MQ_ *I2?*+52#FM!$JS,D(,"&^ 0P:X1^*)Y)05R]QY-7@%0-7HB[B&-YH-+R MG^N$D2G8?JO6+5T==IM,680!D02[ _@IE1_T!Z1BT"T+!9KC-S3UV#\TQT.A M.0X:FN/W0+-\Y8% <_*&II[XA^9D*#0G04-S\BYH9,=['6MF\N.M6/)7V\/9 MH-(+,FVK5F .LO!P:7GK@T4%J/6,"O&)2;ZPNA5W@K\D+(*7S)#<"S" :2LU MAC8\=.P&^_BI%L0ZSNM84RS*>[\D6N9GE&F:M \QA28\2)K&>@>70NT3B3N> M9IC^.WGN/!&WB[W@835LA:2A# \5F[T^8(H8)(-\G%B7N*H;&M97R8QR=Z\ M6VP=7@&N%08!@<8WFRTK[_+8GAL$=*YZ MN=.F[G&K*(C>[W)FDE!J45/L&(L%ITF49 E;_R)//D6";:VRB5P! 1O4-+05 M0: VC(Y. B15CJ&X$X0!2&1'9&_!*@2"XG;AP?K;-\E=@5%OV$-!ZP, I)> M>R8L,F $((- ^ U-*'B!-DLA>J(M G6PL2 M;>7\N)\>KY9)1FTGEVV)LSD),%?-2$9Y$&P IDP6\C+$']#T^*^KOR$=Y;C[ M;_A28)4\=K'?K#@%LD]95:X@Z+"H.;!(@D !]F72<,-1*46%UD=VJH992W., MM+W^CKST-^9>[Z%&:(L +"7:9ZZ'?9M(<_NN:(!#H M,-8Z*2FE2&M]O)!PF++6_8N M;=%P+IG$; .<1&P'KH(6'M;!.C=%BE"Y+AT MNZ+)&@/)"3O5KJ'HL&SR89$&A0KL#QPSJA!TB'&=T3)/<:;2\XM-OO\K^<'2 M2D#G+*=EE\TJJ:5-% 0C7@/;"\E= MOU399=I\F]*F#0BA3H/@^Y-5C$H5@S53WE+&B)E<:JUYQU/BALI]XIB6Q7;N MF$H2$!XV7QT99 326B\L+#:8TL_;-&$DA26+C<$+&6T]M/@K]FCV5^5K!M@-HM&YV6FXQ8I0&QTN4/8$:'H")&I]3U M \_ND%"\R+((M]0B=8P-:-9@IJ4+"1C(7(L62B)UO>6&9VC)T=>4H.R1H,OR M9^CJF>"+>GS]TD@4J17N(U1(Y7QA:#QL*XI@B"$= 6M"RN_U: G]QYVQ5-HBO*,7R5I:%Q MG#&O;<](EG<0!$1 VQ64(B\7HESII?\_8_8DML]9M+\3/")$/6655J-5W_6W M@=%NF7E3DYHT#0H-B+.W^ 4(/%2!:G5\J,U8/B_FJ8?&538W'CTM'K$\@+?; M+%4SJ#0&7P7O#')\>V% XR;#!T1 :$WP"9TPR&/1'GH!U0$HUJTI_.S]) % MD,2?]_?D@0CUWL&2[++/JEJ%X! M6JEGQ,HJT.^J$I378OO]\OJF:_E);M:;Y%\KG!*YY;]02P,$% @ 3HDH M5X^SE:=7!P UU< !4 !A;65H+3(P,C,P.3 X7W!R92YX;6S-G%M3VS@4 MQ]]W9K^#-_N<&^RE4-@.I*23*2TLH>WNOG046TDTR%)&DDGR[5>RXS072SZ\ M^, #!.>OR_]W;-G'EGSQ;I7RZ)DJS:2X;/4[O59$12P3)F:7K2_C]M5X,!JU M(FV(2 B7@EZVA&R]^^OGGR+[<_%+NQT-&>7)>?1>QNV1F,JWT6>2TO/H Q54 M$2/5V^@KX9G;(H>,4Q4-9+K@U%#[1='P>?1[IW\61^TVH-ZO5"12?7D8;>N= M&[/0Y]WNU]5:]S4]1_((S\73N?DV(II'E M)?3Y2K/+EFMWT^SRM"/5K'O2Z_6[_WRZ'<=SFI(V$XY;3%ME*5=+5;G^V=E9 M-_^VE!XI5Q/%RS9.NV5WMC7;;UE O],3S1N\E_W1&:]L'NF9F[':D7=O887BFHJ3.[UUF[8 M*T)7QNY/-"DKK-[M*/VF[?RE+;F/U8*#<]*?O"9;S7/' MR_TY)ZUIW)G)YVY"6=?Y=Q]R$#D$^\_WO*&KB3:*Q*:LB9,)Y7G]WZWF0-)M MH%^:&T5W092MJ!W/&=^& M>:IDZJ.S(2$]'=T%99MHAN:5;3]Q?1AR,JO&>2 !\NQC *UT@T7T/=6Q8@O' MI0;LGA+(]P25;X6WAC&7Q\X#G3'77]<5=\*E;F-X7/ 4 8(_Q1PI@FZ1(G E M1$;X UU(50-^7PGD_1LF[RIO2)C_SH@R5/$UA/21& C[=TS8'H=(O!\5$9HY M/A#@QVH@\3]0+SP\'I&0C^>4W?G=GEK@ M['>* /&_>2WXC]PB1>">*B83>TI7 /9'8B#U,TSJ'H>HO&]$ J6]E8+S'WS8 M!_:04 ^9C@DO>C2TVW08=X4 M:1#&/LQB^L'C6,M%#9*9ADVB$+[D:Q&B77%IJQX'%@/W5L$RAXEK03910G!2,12 M+>3.[>*!S.SQN![()#BDUQ2$A@,EWWR!=92@7"6)Q:4W?VZ9H/U0*"KEX&=$ M> $(V'PEV$]>AOT$CATE#ZVU^4JPG[X,^RD<.THN6FL3$_O ?KQ3CW+I>0+M M%4.1H^2B-18Q@>=GFCMUK^0S*V9%U5$_*@%%CYBBALVB[O#%21ZRMY=**&_$ M=+7:'";G>ZD-X?^Q1=V59+4>RAPQ<0T9;?H&8Q%W=]/"-Y7H0 +EBY*K5MII M&JF+L*+$O_ON*Z! 41+0*C,-\[R5[MG'7(K@_=AC%90K2B;I,]7TP.MF$FOO MH;_S-7@&&\JP>FBC88S?%#.V!P.9IIG8W*/Q/!7S2*%X4=*_H+V&48\E9S$S M3,P^V2M$Q0BOYERE@T)&2?;\QAHF?*^HBS2UE]WY/"ZWU$#=3:>^D3>DAQ)' MR?7JC>*2'VF=4?52_A6EH%% 2?N@IIL>9VB3^Y2&50BAAE 0O8*UAR'O]J,9[((&"168IJ7PBJ/(< QXI%#GBLT.//9RYE\6DYNVYIWAA M1XBXKP04/.)#Q+!9I/EIAKH^LV?ZGABRZ6&(OZ\$E#_B \6P6;3Y\VI@3SPS M&7YF?B"$TD:<"EMI#07R."6<7V>:":J#8\N!$ H9< E#HB#-;@U9QX*]^K",OUK\%R5>HP6\G0,3N-8GUVHTX=A,I MBC.Y2(CR4 _IH=Q1%U;ZC39,_L[,J=J]?LH[,[)Y6VC20WTI:!10TE6H:9QS MZ\Y*_N"I=4\'Y8V8F%89PUDSE4TXBX=D?"[UHMW>#>4%M\XWZYM[#:+?\#4$L#!!0 ( $Z)*%<'8"M7 MVA0 "1S 2 =&TR,S(U-SDT9#%?.&LN:'1M[3UK5^+*LM]=R__0EW/V M6;JVO (HJ,-9".B@ HXPXSA?7$W20,:09/(0V+_^5G4GD$! <,#'/GL_5-+5 MU=7UZJKJ3G/ZW]% (T_,LE5#_Q1+)U(QPG394%2]]RGF.MUX/O;?XN[.:=\! M.(#5[4^QON.8Q\GD<#A,##,)P^HETX5"(3E"F)@ .AY%PDFI5#KYO7[=DOML M0..J;CM4E]FDDZ;JCXOQ8^L$M&-I:@@4G_B#9))SJ*%5F78( A\F16,(U(D$ MS0E0QP=5;2,KI8^6T2$@)AU&BV#32#/,D'T_N[V>@CO1\%/0I&-1W>X:UH Z M($/$E(NGI+AT&$ 2MYD<0@2?$SWCZ5D\^7@F[>.9$TYXIMC=3P, 14JE<_3Z"H:6B:,6!*0F<"+%5(Y6/R7]-">_E\\3LY5IBG'I,6<$]*@ W9,1LKHA-0J_(^'E%1^^-KZ0ZIKVD>R[SP$"_8 +P7U4'%H[+P!N+ M:C5=8:,K-GY(@0]*Y3/9[.$Z> L!O*4!TQ7XWSG7:.^A2S6;K8'J\ P877E( M/WBN0>"$1^O@D!Y:?6HQ^T%ZX)Y0(+'YLW7P5)"6&P]79HZDA<@[AC(FMC/6 MV*=8%_3OF*13ID/:Z@! &FQ(;HT!U0_$@P,@P%*[7-,5])4!4Z3(;0O'RFD$[$B5XI(Y,G0M' L\'#,@D67V0("'>FQ MS5=(&)3P9>^XS[TD#->/^V:1&-E*S&MVP!-\BMGJP-28L'YOJ#!R,9QMN)8_ M&H!Q&1][TR2J,C=-WS/YH(QS=?)T\EQ5L*6K,HMP\EGDDE.N784E,-MY.EPR M&\.\=755 M,!9,:HZ; T9MUV)%S_:. <9'YC>%AT!L"_ +0UXXA,<$#O3B,:8.8VX<,&X0 MXSQOL2\W NH85J!Y?1[,TAB%-3!HA>G&0-6?&_9YOLR.&X78;P]Q88ZAGE4& M;%"X!-_OG2:A/_S&?T]-WU<.J-53]6.2BA7_\Z_T8>KD-&D6%X),&@-KP*VK ML?@-[?&E*NB&1;^X8YC0UX2%PGO0,1S'&'C/AJKB]-')I_Z(A7IW# OH%KW/ M-"H_$@G6 =O05.6$>(T^)M&>GK;CRA&WU;]@78*GTZDA![R?@1DD0U-8FS^K M+E,^ _C,2>J$H#W'J:;VX)$,OHA9P +;I'H0LS^-%,[CM%/\VJBUJQ72:I?: MU=9IL@/SP2[%MZ:K52U_O:VU:]46*34JNSO5[^7/I<9%E92;]7JMU:HU&V]$ M+0>8)"''Q#7!P82PPGMMJHTUNJS?-V_;KC'GC6K9+=8@9DVCK[*\EHV*@HWGV+JR#E6 /L 8/L*'8^!7*9'V7"(F!C(U(1>'8C= M\P<$,2\T[;=TM-E-J?"LJ J>J$3&>,MZJHUKD8-9<[2D+N7;5N'^Z++T:SU) MS6:GX;%BQ=)-\_JZ2>K52JU56N.B=4!JC7)BJ;_=JF#VJB,*)HXT MHA5,J2;4)BV3R9B[*40%ICHV*4,L#=WV7U=;'-K1J&G!%YB7L5(Q_-JFB M^)_7)B00_$YB6MG0-&K:L#K[?_$*AF/YZ)^8Y:@RU7R211#LITRGCN(#>M@S MF3]6C I6J[4L"A.$TM5TV;# K7O?)2 MSX1E:,S!'69:QA,:0M@UK4 ;^&6FT2$XM86FX/URE,6\SFZ7U]D0K\]5C0&1 MX%JC&=L=]NS#:^OR6T?]+4#!*;$!M:Y!*B-EM1>0BY5 .V3%;9& Q4&[<%(RZT/+ M(1]:4A2+V;;WZUK563K:?])OI7[_TASTFKW?\I\1 \:*ZC3^G+CZ.[7T_?UIO%VH%B-%&Q8AF,!I#IZJ+9SDWV/&JR-P90H/U0S<4Q MT M07)?.=7;TK1G%2/C*0::4LEB=+$J7(]9?ZB54_?W[(6J$!PC M5CR4YC:G/='OSZFO7V>Z-B! N>D;^M)\PRS+_8N[QDU9S[V0TMEQP$'FI7A* MRN??1ENWC'Y:Z_C/O_)2^NC$)FVF,1,9X,4_!QB5:2[6&'9W4(C<)K9:!,4B MUBM4>_\&5OV"[5# 1ZCK&)/B3_;YC<^M;&Q^)&%NVSF?0X 6:PH05K$^^BM M5 =$[6+94>\QA;0P$-C=N::V0VYY@7YSR].6E59C75"8"!8Q!;';B:0W5FN+8V M)C8D2'9WS'MZ'8P.C"KR)K&!1*QI8=<%/-;N#M7'?F,73_<-L2/&92IF\/;Q M]CC[D>NYJ8244_7IE)84VGS0WZJK1672=\ B9),]GSCZ^QUWENJ PF!%QM6] M%-J.CAO^*KN%[WV)?=6R+]Z:ZAB&QJC.C\<%(XI(,@3S\B?/E>!6K#S\=&U' M[8Y?S&>/1IAKD$AB!K9GT9&3K)03IL--)K!7BEND>^DC4CZ_)<#4! !NN5+Q MCT6]GD7Y07@+0@ 9!*[WZN"SP7%KT>;DG/V\_^L[&V?;G8V;TSP-[\R6I@2" MP@H*YPTIG:7QM!2PI=!A@XDE95,) ?F/,?UMC*GJ&=.-Q7!-P /,_-P1AC96 ML]M=E-M^OCQKJ)];=X7&>H7-58QJ,2WOS+B T+@+27F=_-5,3 ML/\8V]_&V++1QE:S;9=9SYK<-6/YO%K_TE8WOXX]1]&'-[P,BV?WY-4,SX-] M)K 1E$%PG.1^3(+ M(]9)(EJ]68F^Z<"K"U(N\C3+M(?_E@(OV+W0 ;3QE4UQ2%3N$UFCMKW4^7S< MB5H4<9'6>- QM#U[^?Z_F,DZD\BE7F$2_EE&+BSF^UTP]6%?A2=3?["ADR&K M2'OANS+K:L.VF;=HU]YSJ..TU.'6$!TT='XTROIM_?QPE'[A'M3L.+$B1@H@ MO)9CR(\O.?;VMQ;/H2<>SW"%W4;+YN=%-I/MVI>7-?I"V80&B17QS?#?$(BE M]OI13/UH(FE#W# KEOR,U?C1W^)CYR5ME!V4I5+=>?$+ OQT!?J[^8,5472@ MH[05^FO180IN<*1.K4?FD.OK\BLGAMO8?JGI"@;MC'3&1.9;,=#E$=8%QL]1 MSNR3J#8!H4+$CUA[I&<90Z>/L;^)6R?4)@KKJKHX'"\JQ*F<'TC.E(?%&S09 MLH>3/#KA5>)4SGN[!\8!J9AXKA[WOT0&(77B4@2RJ/=R)E@QFYCV"Z!-O.N8 M=NGK<=5H]OM4")5\27:<"9T-\H>YX*.4Q2 +7K>[&^;KP_KW[/?#C2?&2XA9 M-2=^KX*.LL?EHJ]UE]C? 5A=I#&K<_N=?3!5ID&Z!Z:J&SSY4(HWO]'-@!*\/Q783K'@+5Z&?RY<";PL_^9G M1F;%&&89#G4"_7ZY6-T"]&)<'K+-LV!A4!9D<%J*X/ AC["F98M@F6*VC!$> M<[[^,%.GF'^E>G$2!P1&.J*HMV1"A=W(MXV>@YC%@5&3'S/Y%T+,(R,A[G,WYX0U#LS/')0][:J=NO)_H4EJQ7L M_#GU$,6MN?I]K+A R&E>UN\4:PX;D'0"3_9V)K#84,5WW/#\CD$H\?=M205C M1Y4?NBWU+,;KRHEIUZ"F;,IA;N65^EBQ";GY[$O&!Z3$;PPC=8:+M$8^&QI? MJ?B!R@39PR4/3UU*J9.R']'!I_3)_NX.S]%X6 TL\^)?0U?(Y"XF7$3Y!P"" ME9;<,GZF7"%EZ*8Z4X;RUCL*3+9"0TXP^8,2;Z0 UMV=A6@/B,*?4WZ.^M+5 M(5X_Y!-/'V T@J/2@0&1 .(L^P$+@(-+@R@&SY5BB\9W/"!*H);#CV]9S#$. M>/>VY4+X0LZH_GBPNP,]J3( ?<&(ANL,6"I,;P\;!,D"H\_2&8+]:29@@DB6 MX:4[0B*3B7.6[:G[0DU4708OA$&.H-5Q\-083%@6V&VW Y&(K&H0L9*N90S( MOZ5<(D4@-M$PO &6_CN7FCXX =3J_B1R$N?.K &RD,=9*M[K"/[ \E[ZP1CN MEZM:XLQ;A^& SRJHP"/=W<"K/6EY_,3!J?DE\M?5=;&I$-M%;PGLA4H !*& MJ!&"@ND;SE5\[9\+%$R3NIK@;B#%"[$)-*9/(0.3(3,#"G=WICL]\]IB,8WR MP-"C,Z#Q_-0Q&(CL:I/C>F5#YZLJU[&VX8#Y-# %9Z#&Z*%O$3**.C'R[LYD MZ'T^:9..N621T$T0B9Z \-81%QF8$_UMQV0 M.B1/QC3"#BH C]9=4W PP%V;Z^]J_$7.A"!K/L_*1E@0G$N+I$$"PO!YR.>V MN^--SI.1BEX'[!K >ZC\( 04R;^E5.H@E4K-Z#CW)KY@8<"NJVE^*O&\<(GB M,I\:H"/(:L1+06-MM "__K#82-YU90&5A79 6B :6[94,W@@=NKQ% -P8F(( M21J_$T2X&^Z4F,/PI*R"Q2#P/S\A=2.^CP9=UD*W(^#[BN#"P>.,A5?E4N'7 M[\T."AA@ ).?P!7;$C! 5]7$JG)*B;@8T!E(&2EW5,@JZ0]V^3%UQ)@1N^MKZ<=B]_)VS 2H9OQEIP#E/Y8Z;A@(?J< MQ(;G49E&1;/T>QM\7!;+M]0[LZ7 9TMND[G\7I2S.5:(.,F;/%T@P$6:N$R: M:_')1_ANV+*)LDNX5#+)#@73)L6B4,UD:>5HIHH">=O0L!XGP'6JTYZ7=4_ M>Y!S0DQCK%=U(0N*+I 8V[:+V7P'P'@WQ&KCZW/XI0L>_@29U:CE)K6ZU6Q0 M[;.1+FNI2B_4VHV1Q=-KOB\A4FY0;V1^A3J4\*MI>)E YE!8+"?X-1?$H3V0 ME\4(ZI>"*HI% "\5%U^'(0 5[Y[$J/.V>(WSW^(ZF8B]L=F-'FFK&SUK[4$$ MAP]M?)B0'&U,9&I*RK1JNU?!^M5FH$L:#!$6:?#^E3KXB*% MB'A"[0'@VN'"RK*[P_%1U^D;%K@R9+*J9GL3?)-KQN^'A^)W!I4A0]ORF% M&R7P#/JL]Q]*7Y)?KY+WR4[\Z^Y;/=RZTFE6K/;)^>CP>W"E59> 4 M;+WP@S5:/[_(@X:;NZI\N[U*6_2L/VCFCZY*9<=UZU\N^J.2/79_UJ^^'.8S MS:^]I_R=6;AOWI3MF\/JX+%5,>S!0/JJNZ5DHW^CW.4'RE$U[0[.&J5\YYM]T?TE7=2&R;.LN^;E0 M_2[]ZE^>ESY]$JSX?U!+ P04 " !.B2A7+7A@YSX= #BZ0 %@ '1M M,C,R-3ES(CF6_TX$_X.F=J;#CL!G'5-M>QR; M'+:9ML$+N"LZ-O:#2 1H*LED\K"+_NOWO2UQ=MLF)Z'%!*J4GZ1V_ M=TB<70UNKL^KE;.KEM6$OPS_=S9H#ZY;YV<'ZB\\/="/S^K=YF^L/_CMNO6/ M=V//#4_8T>$\9 ,Y$P'KB ?6\V;X(R?N M"?/E9!J>LAGW)Q(^'KX[/ZN?M[Y-Y5"&T/7^T=E!'0BYS761:O^3.PSFI\M- M-J4N-3@T/3QE:?)LX8;")Z+ZK4:WTV363:O3A/\&;-!5'UKP)3SHM?H#:P ? M&KU6LSVH5JS+7JM%+?'Q%ZO]:ZM7/)L_2*J9^W==@7]%02C'"_VE=$<".SW< M_RC==^>#JW:?%:\-S'_UXK!5:U-C(QZ*$>,!\\9 W3P4LZ'PU0P_U]CQX?%[ MMA-.9[-09M9GPDJI7A@G$7^IQY M[@2IM6Z[U]===@.4-*QK=M6];K8[E_V:&J7=:>PK4CAK"H<_<%\PV_/GGL]# MZ;DXO$B-7O=\WWL0?G9P&*;3&GSI]GXQXU0K-U;'NJ19%PS5@/4>>[XK^;K! M+B/N70 MTX)!*Q%ZN.9ZH&M83^$'NG_J"^8SZ-VU^P-6MSJ_***ERV08,)O/N2W#!79@ MC6;2E4&(U-\+9DU@5]@.- PBH-"TK+'LK+)O >=,O]9Q>X[ZUL+KH@&*F>]\9\)IW%R6-]4]M _BX4 M*=#3W?D76D=%]MUY._-ID/G4R7QJ93[UUWQJK>GS"C^='>"$SD]>RSZL57E? MKEJ]EM57+&QDGSY5*YH[B1GQ<:$TH#J9R\'W*0$M)DJ/Z@ M@YX(0M*%#5^,P!A:$U\(U'(9%?G/R!5J,8X^D7H\JE9VX!'7/8'NRXQP(?T@ M9+'&1 J>/FA3V"FU?'Q( Q_7C!"2WGF0 :R()J/&?-UQ#33!?.Y0G] ?B/7, M&\FQA'^/?6_&0M@D6A;\._\ M&/8KU)LQ]QENG'+@O:$0+IE#I@Q:ABE:]_">WMDQCYQ0O>/9=N3[FC.4%71A MF4GI1M@WV^&[B5(0MK8LG_>/=NS=1 ^0_;@[QZ]'J:^UO5KBM!W;V8I>> "-)N[Y$?GK;@0=!&I#_<%YZ3".W/_D!-@K8F$LG\HGS.,X: M>,U9@+UR[,A!OL,I^#2@HAGFZ3E2R<3 "\&X=D0(*WXO?#X1K(?&&^VC:CR; M.Q)L,.Q0 U8G-8:7W2BB/X 7?BR9%+U8KZLT;[MM3_=91 K$RJQX-_P4[ MPFX551G3/(J$$='4*NY(S1G)&NKNEM>N6L'%:XIA&".. );BWY'TC08#\1< M9"1AHE!I 7RR8^EAI NHR0<:8=M@4I%-JSB"/@$'!A&N/JQE &RBU,P4J<1] M QT#RSN'?P$^C-RP6H&>VRZ^*4:N" *V\S"5 %X 3L*FS&2(=,,,AT(/!!^5 M-%Q:UFV-#2,N+H][O<\ I07".+;D0BQJ8LT%RQ3M9+P6'J9U+ XEY4: M$,#A3EVO$9($DW6B$;94&P;+HN:-9.!*:7'WHA 4MDLMKP7,P4="@8%5_PE6 M7"$**3*!@D8A!0T^E]C^6O! L.X0U!^!WN#1[JN5#+< O3O-E9,$SA%*C=G M4H'B(5!E@835TR@[^X;F/6,@8:?L*9*HGLVXVBAL%"Z(7S@+09^+,]N/9^C37K%FM*/G&!N:4-3@;L M#PKY)8C]G):F'[FL 7B8OK[F0W0M/%^B,:*5DT94?63/G')KU=N#IL7(A3*< M A.'GK3,NX+6VP-SSZ":86D11,8*"ATD0)(T,8?4$GYMJV4;"]A55*T& MURC\:$QIRE!!]PX:8;V?P-JQ_6"6>@8\C)810%HBIM5*+*<;X9 W"#G-Y@%" M!*2'X@/;@08.)6^USZ,A:<^(F\&F.T=:0AXXMLZN[#(L):$ZUJ^0;V'VNEH! MAKD'S:GUYEJC"(K/<9 U9YYQQA"C^( = E!GP$(@*4/A> \D0F]K%P.-Y;0H M(/" G<25!9LXTI8G60;$6M(M\C<>VUOT&!ZDXY!5]=A&.ZP(43N[=@M?<%#G M71+A_'H!NX8Q.0&%/Q"FT!X$!+ K=LKT]'6\_:[9_S0:V]T)O#DV.YW%H M?&_HA:$W.V&?\#LP>;#$\7=UAX-M/8+!R1X! [F$T2LT_T"7:&<771[K1J9 M(F1GU$Y9O*D5%$"7>XQRB)E$1R")V4X\3\'P>^Y$9(HR[]9A)D2FD"4T,WK65G@9 M.A\IW

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